Abeona (ABEO) Director Disposes of 4,718 Shares After Vesting

Rhea-AI Filing Summary

Eric Crombez, a director of Abeona Therapeutics Inc. (ABEO), reported a sale of 4,718 shares of the company's common stock on 08/14/2025. The sale was executed to cover tax obligations arising from the vesting of restricted stock awards and was reported at a weighted average price of $6.9273, with individual trade prices ranging from $6.77 to $7.05. After the reported disposition, the reporting person beneficially owned 42,427 shares. The filing discloses the transaction code "S" indicating a sale and affirms that detailed per-trade price information can be provided on request.

Positive

• Sale was explicitly to cover tax obligations from vesting of restricted stock, indicating an administrative, not opportunistic, transaction.
• Reporting person retains 42,427 shares after the sale, maintaining continued ownership interest in ABEO.

Negative

• Insider disposed of 4,718 shares, which reduced direct holdings and may be observed by investors as insider selling activity.

Insights

Corporate Governance Expert

TL;DR: Routine insider sale to satisfy tax liabilities; director retains meaningful post-sale ownership.

The Form 4 shows a sale that is explicitly tax-driven rather than linked to a corporate event or a scheduled 10b5-1 trading plan. Such sales for tax withholding are common after restricted stock vesting and are generally viewed as administratively motivated rather than signaling a change in director conviction. Post-transaction ownership of 42,427 shares suggests continued alignment with shareholders, though the filing does not disclose percent ownership so materiality relative to outstanding shares cannot be assessed from this form alone.

Securities Analyst

TL;DR: Insider sold 4,718 shares at a weighted $6.9273 to cover taxes; transaction appears routine and non-material absent context.

The sale covers tax obligations from vested restricted stock awards, per the filing. The reported weighted average price and range ($6.77–$7.05) provide transparency on execution prices. Without additional information on total dilution, recent trading patterns, or the director's historical activity, this single tax-driven disposition should be treated as operational rather than informational regarding company fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crombez Eric

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		S(1)		4,718	D	$6.9273(2)	42,427	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.77 to $7.05 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Eric Crombez	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for ABEO?

Eric Crombez, identified as a director of Abeona Therapeutics Inc., filed the report.

How many ABEO shares did the reporting person sell and why?

4,718 shares were sold to cover tax obligations associated with the vesting of restricted stock awards.

At what price were the ABEO shares sold?

The filing reports a weighted average sale price of $6.9273, with individual trades in the range $6.77 to $7.05.

How many ABEO shares does the reporting person own after the sale?

The reporting person beneficially owned 42,427 shares following the reported transaction.

What does transaction code "S" mean on this Form 4?

On this filing, the transaction code S is used to denote a sale of securities; the form explains the sale was for tax withholding related to vested restricted stock.